BMO initiates Prime Medicine stock with outperform rating

BMO Capital initiated coverage on Prime Medicine (NASDAQ:PRME) on Tuesday, assigning an "outperform" rating and setting a price target of $9.00 per share. This represents a nearly threefold upside potential from the current stock price of $3.05. However, InvestingPro data indicates the stock may be overvalued compared to its estimated fair value.

The brokerage emphasized Prime Medicine's proprietary Prime Editing platform as a differentiated, next-generation gene-editing technology capable of precise DNA modifications without causing double-strand breaks. Their lead programs, PM577 targeting Wilson's Disease and PM647 for Alpha-1 Antitrypsin Deficiency (AATD), are progressing towards initial clinical readouts in 2027.

BMO Capital believes the positive and differentiated profiles of these programs could validate Prime Medicine's potential as a best-in-class, blockbuster company. The firm noted that clinical readouts could reduce risk to the company's in vivo editing platform and provide valuable insights for its broader pipeline.

While 5 analysts have raised their earnings estimates for the upcoming period, Prime Medicine is currently experiencing significant cash burn with a negative free cash flow of approximately $157 million. Investors seeking more in-depth analysis can access 8 additional ProTips and a range of financial metrics on the platform.

In related news, Prime Medicine recently received a favorable arbitration outcome in its dispute with Beam Therapeutics over the investigational therapy PM647 for Alpha-1 Antitrypsin Deficiency. The tribunal ruled that PM647 falls within Prime Medicine's licensed field, eliminating any monetary damages owed to Beam Therapeutics. This positive development has been acknowledged by H.C. Wainwright and TD Cowen, who have both maintained a "Buy" rating on the stock and reiterated their price target of $8.00.

Furthermore, H.C. Wainwright upgraded Prime Medicine from a "Neutral" to a "Buy" rating following New Zealand's Medicines and Medical Devices Safety Authority approval of the Clinical Trial Application for PM577a, a treatment for Wilson's Disease patients with a specific genetic mutation.